We hereby inform you that the Board of Directors in its Meeting held on November 11, 2026 inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors, for the Quarter and Half Year ended September 30, 2026.

BAFNA PHARMACEUTICALS LIMITED REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294TN1995PLCO30698 Date: November 11, 2026 BSE Limited, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Mumbai - 400001. Bandra East, Mumbai – 400051. Scrip Code: 532989 Scrip Code: BAFNAPH Dear Sir/Madam, Subject: Outcome of Board Meeting held on November 11, 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held Today (i.e) November 11, 2026, inter-alia considered and approved the following: i). The Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company, for the Quarter and Half Year ended September 30, 2026, as recommended by the Audit Committee. Accordingly, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2026 along with the Limited Review Report, are enclosed herewith. The Meeting of the Board of Directors commenced at 02.35 P.M and concluded at 03.50 P.M. We request you to take the information and documents on record. Thanking You. For BAFNA PHARMACEUTICALS LIMITED Mohanachandran A Company Secretary & Compliance Officer Enclosed: As Above Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com BAFNA PHARMACEUTICALS LTD CIN: L24294TN1995PLC030698 Corporate Office and Registered Off Bafna Towers, New No. 68, Old No 299, Tambu Chetty Street, Chennai-600001 (Tamil Nadu) Email : cs@bafnapharma.com, Web : www.bafnapharma.com Statement of Unauy d Financial Results for the Half Year and Quarter Ended 30th September 2026 (INR in Lakhs except as Stated) Particulars Quarter Ended Period Ended Year Ended 30th 30th June 30th 30th 30th 315t March September 2026 September | September | September 2026 2026 2025 2026 2025 (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) 1 Revenue from Operations 4766.56 2.658.32 354682 742488 700922 | 15.061.74 Other Income 11341 191.10 11797 30451 17753 475.63 2 Total Income 4879.97 284942 3.664.79 7.729.39 718675 | 15.537.37 EXPENSES Cost of Material Consumed 2,107.00 143150 191863 3,538.51 367441 8.213.53 Manufacturing Expenses 597.24 488.75 499.62 1.085.99 1,007.58 2,050.82 Change in Inventories of Work-in-Progress 40125 (170.44) (112.09) 23081 (134.05) (15.96) and Finished Goods Employee benefits expenses 55213 561.63 549.05 111376 1113.04 2,191.89 Finance cost 102.00 9370 8643 195.69 17697 366.11 Depreciation and Amortization expense 186.84 17807 14727 36491 284.26 607.26 Other expenses 24869 258.70 26339 507.39 413.16 102670 3 Total Expenses 284191 335230 7.037.06 653537 | 1444035 4 Profit/(Loss) before Exceptional Ttems & 7.51 31249 69233 65138 1.097.02 tax (2:3) 5 Exceptional Ttems - - - - - 6 Profit/ (Loss) before Tax (4-5) 751 31249 69233 65138 1,097.02 7 Tax Expense - Relating to Previous Periods - B 5 5 - (12.96) 8 Profit/(Loss) for the Period (6-7) 684.82 7.51 31249 69233 651.38 1,109.98 9 Other Comprehensive Income 6.08 6.08 (4.62) 12.16 (9.24) 2433 10 Total Comprehensive Tncome for the 690.90 1359 307.87 704.49 642.14 113431 period (8+9) 11 Paid up Share Capital 2,365.63 2,365.63 2,365.63 2.365.63 2365.63 2365.63 (Face Value of2 10 each) 12 Other Equity as per the Balance Sheet 8,489.62 6,757.16 7.249.32 13 Earnings Per Equity Share Basic (in INR) 2.89 0.03 132 2.93 469 Diluted (in INR) 2.89 0.03 132 2.93 469 otes 1 The above unaudited financial results for the quarter and half year ended 30th September 2026, have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their mectings held on 11th November 2026. The Statutory Auditors have conducted a "Limited Review" of these financial results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure| Requirements) Regulations, 2015 2 The figures for the quarter ended 30th September 2026 & preceding quarter ending 30th September 2025 are the balancing figures between the unaudited figures for the half year ended 30th September and the unaudited published figures for the three months ended 30th June. The] figures for the corresponding previous periods have been regrouped and reclassified wherever necessary, to make them comparable. 3 The above results have been prepared in accordance with Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally| accsnted in India Company's business relates to the manufacturing of pharmaceuticals formations, which in context of Tndian Accounting Standards 108 (Ind| AS 108) as notified under Section 133 of the Companies Act, 2013 is considered as the only segment 5 The Company has received orders from the Goods and Services Tax authorities, including a demand order raising a GST liability amounting to INR 235.47 Lakhs and another order issued by the Joint Commissioner towards recovery of GST refunds availed during earlier years| amounting to INR 331.09 Lakhs, along with applicable interest and penalty. The Company has preferred an appeal against the GST demand| of INR 235.47 Lakhs. In respect of the recovery of GST refunds, the Company has obtained a stay for the amount of INR 331.09 Lakhs based on the writ petition before the Honorable Madras High Court. Based on the underlying facts of the cases, applicable legal provisions, judicial precedents and prevailing indusiry practices, the Company is confident of prevailing against the positions adopted by the GST authorities and| accordingly, does not anticipate any adverse financial outcome. For Bafna Pharmgceuticajs Limited Place : Chennai Hemalatha Dat 11th November 2026 ‘Whole Time Director . (DIN: 02714329) %”? S R0 pcc® BAFNA PHARMAC Al D CIN: 1.24264TN1995PL.CO30698 Corporate Office and Registered Office: Bafna Towers, New No. 68, Old No 299, “Tambu Chetty Street, Chennai-600001 (Tamil Nadu) Email cst@bafnapharma.com, Web : www bafnapharma com Statement of Assets and Liabilities as at 30th September 2026 (INRin Lakhs except as Stated) Asat Asat Particulars 30th September, 2026 | 31st March, 2026 (Unaudited) (Audited) I ASSETS (1) Non Current Assets (a) Property, Plant and Equipment 8,803.62 8,179.02 (b) Capital Work in Progress 21671 31340 (¢) Financial Assets (i) Investments 0.05 0.05 (ii) Other Financial Assets 9630 95.56 Total Non Current Assets 9,116.68 8,588.03 (2) Current assets () Inventories 3,219.90 2.890.30 (b) Financial Asscts (i) Trade reccivables 5,002.54 439292 (ii) Loans 10.77 7.74 (iii) Cash and cash equivalents 129.45 20245 (iv) Other financial asscts 17126 17125 Total Financial Asset 531402 477436 (c) Current tax assets (Net) 17.00 10.63 (d) Other current assets 1,632.69 1.289.92 Total Current Assets 10,183.61 8,965.21 Non Current Assets Held For Sale - - Total Assets 19.300.29 1755524 m EQUITY AND LIABILITIES (1) EQUITY () Equity Share Capital 2,365.63 2.365.63 (b) Other Equity 7.953.81 7.249.32 Total Equity 1031944 9,614, (2) LIABILITIES (A) Non Current Liabilities () Financial Lial (i) Borrowings 142284 174822 ‘Total Financial Liabilitics 142284 174822 (b) Government Grant 383.18 399.50 (©) Provisions 4161 41.61 Total Non Current Liabili 1.847.63 2,189.33 (B) Current Liabilities () Financial T iahilities (i) Borrowings 2,295.87 1.965.11 (ii) Trade payables 2) total outstanding dues of micro and small enterprises 577.76 113254 b) tota [Showing first 8,000 characters — download PDF for full document]